Clinical Trial Detail

NCT ID NCT03685591
Title PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Pfizer
Indications

prostate cancer

Advanced Solid Tumor

Her2-receptor negative breast cancer

Therapies

Enzalutamide + PF-06952229

Letrozole + Palbociclib + PF-06952229

Palbociclib

Age Groups: adult senior

Additional content available in CKB BOOST